The mechanism of SOX2 in the development of neuroendocrine lineages and its regulation of cell pliancy

Information

  • Research Project
  • 10004075
  • ApplicationId
    10004075
  • Core Project Number
    P20GM103620
  • Full Project Number
    5P20GM103620-08
  • Serial Number
    103620
  • FOA Number
    PAR-16-241
  • Sub Project Id
    6032
  • Project Start Date
    -
  • Project End Date
    -
  • Program Officer Name
  • Budget Start Date
    9/1/2020 - 4 years ago
  • Budget End Date
    8/31/2021 - 3 years ago
  • Fiscal Year
    2020
  • Support Year
    08
  • Suffix
  • Award Notice Date
    9/9/2020 - 4 years ago
Organizations

The mechanism of SOX2 in the development of neuroendocrine lineages and its regulation of cell pliancy

PROJECT SUMMARY Cancer, especially pediatric cancer, is a devastating diseases effecting a broad swath of humanity and consequently we must be able to understand the development of cancer in a holistic manner to develop the next generation of therapies. While there has been significant progress in elucidating genetic mutations which drive cancer initiation, many genetically engineered mouse models of cancer have indicated that necessary genetic mutations are oftentimes insufficient for tumor formation, i.e. not all cells harboring the necessary mutations form a tumor. Therefore, there must be other factors which license a cell with the capacity to form a tumor when the necessary mutations are present. We hypothesize that these cells are licensed as a consequence of the prior development of the cell. A cell's development is guided in large part by master regulators which are the key genes to define cell identity. As master regulators can induce cells to switch identity, a process known as reprogramming and which shares many characteristics to tumor initiation, we expect that misregulation of master regulators throughout development may be involved in the licensing of cells for cancer formation. We have shown that the master regulator, Sox2, is required for the formation of tumors that are initiated by the loss of the retinoblastoma tumor suppressor (Rb). Notably Sox2 is the master regulator to define the few cell types which form tumors when Rb is lost, most commonly neuroendocrine cells. We will therefore investigate the regulation of Sox2 during development in these neuroendocrine lineages and determine if misregulation of Sox2 is responsible for cancer licensing. We will pursue this investigation by pursuing the following aims: 1) To understand the mechanism of Sox2 regulation during development and how this goes awry in tumor formation, and 2) To determine if Sox2 derepressed cells are tumor initiating upon Rb-loss. We anticipate that the successful completion of these aims will lead to a greater understanding of how development might induce cancer later in life, and provide new avenues for cancer therapies and preventation.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    P20
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
    186718
  • Indirect Cost Amount
    119485
  • Total Cost
  • Sub Project Total Cost
    306203
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NIGMS:306203\
  • Funding Mechanism
    RESEARCH CENTERS
  • Study Section
    ZGM1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SANFORD RESEARCH/USD
  • Organization Department
  • Organization DUNS
    050113252
  • Organization City
    SIOUX FALLS
  • Organization State
    SD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    571040569
  • Organization District
    UNITED STATES